PMID- 37303973
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230613
IS  - 2049-9469 (Electronic)
IS  - 2049-9450 (Print)
IS  - 2049-9450 (Linking)
VI  - 19
IP  - 1
DP  - 2023 Jul
TI  - Pertuzumab as second‑ or later‑line therapy for human epidermal growth factor 
      receptor 2‑positive metastatic breast cancer: A clinical experience.
PG  - 52
LID - 10.3892/mco.2023.2648 [doi]
LID - 52
AB  - Trastuzumab and pertuzumab with taxane-based chemotherapy are considered the 
      first-line standard therapy for human epidermal growth factor receptor 2 
      (HER2)-positive metastatic breast cancer (mBC). Pertuzumab is also a later-line 
      therapy for mBC in Switzerland, although limited safety and efficacy data are 
      available. The present study assessed the therapeutic regimens, toxicities and 
      clinical outcomes after second- or later-line pertuzumab therapy in patients with 
      mBC who did not receive pertuzumab as a first-line therapy. Physicians from nine 
      major Swiss oncology centers retrospectively completed a questionnaire for each 
      pertuzumab-naive patient who was treated with pertuzumab as a second- or 
      later-line therapy. Of 35 patients with HER2-positive mBC (median age, 49 years; 
      range, 35-87 years), 14 received pertuzumab as a second-line therapy, 6 as a 
      third-line therapy, and 15 as a fourth- or later-line therapy. A total of 20 
      patients (57%) died during the study period. The median overall survival was 74.2 
      months (95% confidence interval, 47.6-139.8 months). Grade (G) 3/4 adverse events 
      (AEs) were reported in 14% of patients, with only 1 patient discontinuing therapy 
      due to pertuzumab-related toxicities. The most common AE was fatigue (overall, 
      46%; G3, 11%). Overall, congestive heart disease occurred in 14% of patients (G3, 
      6%), nausea in 14% of patients (all G1), and myelosuppression in 12% of patients 
      (G3, 6%). In conclusion, the median overall survival of patients who underwent 
      second- or later-line pertuzumab treatment was similar to that reported for 
      patients who underwent first-line pertuzumab treatment, and the safety profile 
      was acceptable. These data support the use of pertuzumab for second- or 
      later-line therapy when it was not administered as first-line therapy.
CI  - Copyright: (c) Biskup et al.
FAU - Biskup, Ewelina
AU  - Biskup E
AD  - Department of Basic and Clinical Medicine, Shanghai University of Medicine and 
      Health Sciences, Shanghai 201318, P.R. China.
AD  - Department of Advanced Biomedical Sciences, Federico II University of Naples, 
      I-80131 Naples, Italy.
AD  - Department of Medical Oncology and Breast Cancer Center, University Hospital 
      Basel, Spitalstrasse 21, 4031 Basel, Switzerland.
FAU - Sartorius, Celine Montavon
AU  - Sartorius CM
AD  - Department of Medical Oncology and Breast Cancer Center, University Hospital 
      Basel, Spitalstrasse 21, 4031 Basel, Switzerland.
FAU - Muller, Andreas
AU  - Muller A
AD  - Canton Hospital Winterthur (Med. Oncology), 8400 Winterthur, Switzerland.
FAU - Leo, Cornelia
AU  - Leo C
AD  - Department of Gynecology, Canton Hospital Baden, 5404 Baden, Switzerland.
FAU - Nussbaum, Catrina Uhlmann
AU  - Nussbaum CU
AD  - Department of Internal Medicine, Canton Hospital Olten, 4600 Olten, Switzerland.
FAU - Georgescu Margarint, Elena Laura
AU  - Georgescu Margarint EL
AD  - Shanghai East International Medical Center, Shanghai 200120, P.R. China.
FAU - Koychev, Daniel
AU  - Koychev D
AD  - Tumor Center ZeTuP, 8640 Rapperswil, Switzerland.
FAU - Schreiber, Alexander
AU  - Schreiber A
AD  - Canton Hospital Aarau, 5001 Aarau, Switzerland.
FAU - Taverna, Christian
AU  - Taverna C
AD  - Canton Hospital Muensterlingen, 8596 Munsterlingen, Switzerland.
FAU - Thorn, David
AU  - Thorn D
AD  - Oncology Private Practice Basel, Department of Medical Oncology, University 
      Hospital Basel, 4052 Basel, Switzerland.
FAU - Vetter, Marcus
AU  - Vetter M
AD  - Medical University Clinic, Canton Hospital Baselland, University of Basel, 4410 
      Liestal, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20230518
PL  - England
TA  - Mol Clin Oncol
JT  - Molecular and clinical oncology
JID - 101613422
PMC - PMC10251341
OTO - NOTNLM
OT  - human epidermal growth factor receptor 2
OT  - metastatic breast cancer
OT  - overall survival
OT  - pertuzumab
OT  - second-line therapy
OT  - trastuzumab
COIS- AM: Honoraria: Roche Switzerland, Novartis, Pfizer, Amgen, and Tesaro; 
      Consulting/advisory role: Roche Switzerland, Novartis, AstraZeneca, Pfizer, and 
      Amgen; Expert testimony: Roche Switzerland; CL: Honoraria: Pfizer and 
      AstraZeneca; Consulting/advisory role: Pfizer and AstraZeneca; AS: Honoraria: 
      Amgen, Roche, Pfizer, MSD, BMS, Lilly, Celgene, and Merck; CT: 
      Consulting/advisory role: Celgene, Amgen, and Janssen; Research funding: Celgene. 
      DT: Honoraria: Roche; Consulting/advisory role: Roche; MV: Honoraria: Roche, 
      Novartis, and Pfizer; Consulting/advisory role: Roche, Novartis, and Pfizer; 
      Research funding: Roche. EB was supported by Krebsliga Schweiz, BIL KFS 
      4261-08-2017. All other authors declare that they have no competing interests.
EDAT- 2023/06/12 06:42
MHDA- 2023/06/12 06:43
PMCR- 2023/05/18
CRDT- 2023/06/12 04:00
PHST- 2022/12/29 00:00 [received]
PHST- 2023/03/27 00:00 [accepted]
PHST- 2023/06/12 06:43 [medline]
PHST- 2023/06/12 06:42 [pubmed]
PHST- 2023/06/12 04:00 [entrez]
PHST- 2023/05/18 00:00 [pmc-release]
AID - MCO-19-1-02648 [pii]
AID - 10.3892/mco.2023.2648 [doi]
PST - epublish
SO  - Mol Clin Oncol. 2023 May 18;19(1):52. doi: 10.3892/mco.2023.2648. eCollection 
      2023 Jul.